Published in Proteomics Weekly, March 20th, 2006
According to a study from the United States, "Amplification of the protein product of the HER-2/neu oncogene in primary breast cancer specimens is associated with an adverse prognosis. We hypothesized that overexpression of HER-2/neu would predict metastases to the SLNs. A retrospective review of a prospective nonrandomized evaluation of 1055 clinically node-negative breast cancer patients undergoing 1063 SLN biopsies was performed."
"HER-2/neu analysis was performed by immunohistochemistry and, in selected cases, by fluorescence in situ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.